Occurrence of vancomycin-resistant enterococci in relation to the administration of glycopeptide antibiotics
Language English Country Czech Republic Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
10743728
Knihovny.cz E-resources
- MeSH
- Anti-Bacterial Agents pharmacology therapeutic use MeSH
- Enterococcus faecalis classification drug effects isolation & purification MeSH
- Enterococcus faecium classification drug effects isolation & purification MeSH
- Enterococcus classification drug effects isolation & purification MeSH
- Humans MeSH
- Microbial Sensitivity Tests MeSH
- Vancomycin Resistance * MeSH
- Teicoplanin pharmacology therapeutic use MeSH
- Vancomycin pharmacology therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Anti-Bacterial Agents MeSH
- Teicoplanin MeSH
- Vancomycin MeSH
Occurrence of vancomycin-resistant enterococci and its relationship to the administration of glycopeptide antibiotics (vancomycin, teicoplanin) was described. A total number of 628 strains of the genus Enterococcus was isolated in the Hemato-oncologic Department of the University Hospital in Olomouc in 1997. Seven strains (1.1%) were found to be resistant to vancomycin. Five of them were identified as Enterococcus faecalis of phenotype VanB, and two strains as E. faecium of phenotype VanA. The administration of vancomycin and teicoplanin in the Hemato-oncologic Department amounted to 85.7% and 89.2%, respectively, of the total consumption of these drugs at the University Hospital.
